Pancreatic cancer halted by virus injection in three patients
Summary
A virus injection therapy halted pancreatic cancer in three patients, offering a promising new approach against one of the deadliest cancers.
Similar Articles
@WSJ: An experimental cancer vaccine kept melanoma from coming back. It’s the first successful late-stage mRNA study validati…
An experimental mRNA-based cancer vaccine has successfully prevented melanoma from returning in a late-stage study, marking the first validation of decades of custom-treatment research.
@YannickBuccella: The newer generation cancer vaccines aren't like the HPV shot (that prevents a virus). These are therapeutic, they trea…
The article discusses the advancement of therapeutic cancer vaccines using personalized mRNA technology, highlighting recent positive Phase 3 results for melanoma and ongoing trials for other cancers, with potential approvals expected by 2027.
Daily pill can double survival time for deadliest cancer, trial shows
A clinical trial found that the daily pill daraxonrasib doubles survival time for patients with pancreatic cancer, offering a significant breakthrough in treatment with fewer side effects compared to chemotherapy.
@EricTopol: The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the mo…
Eric Topol highlights the remarkable progress in cancer immunotherapy, with vaccines achieving cures or remissions in refractory cancers like pancreatic, melanoma, glioblastoma, renal, and triple-negative breast cancer, and directs readers to his Ground Truths newsletter for more.
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 melanoma trial, which could establish a new personalized treatment paradigm for cancer.